期刊
JOURNAL OF CLINICAL INVESTIGATION
卷 130, 期 2, 页码 853-862出版社
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI130038
关键词
-
资金
- NIH [R01CA181217, NCI K99CA222617]
Oncogene-targeted and immune checkpoint therapies have revolutionized the clinical management of malignant melanoma and now offer hope to patients with advanced disease. Intimately connected to patients' overall clinical risk is whether the initial primary melanoma lesion will metastasize and cause advanced disease, but underlying mechanisms are not entirely understood. A subset of melanomas display heightened peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1 alpha) expression that maintains cell survival cues by promoting mitochondrial function, but also suppresses metastatic spread. Here, we show that PGC1 alpha. expression in melanoma cells was silenced by chromatin modifications that involve promoter H3K27trimethylation. Pharmacological EZH2 inhibition diminished H3K27me3 histone markers, increased PGC1 alpha. expression, and functionally suppressed invasion within PGC1 alpha-silenced melanoma cells. Mechanistically, PGC1 alpha silencing activated transcription factor 12 (TCF12), to increase expression of WNTSA, which in turn stabilized YAP protein levels to promote melanoma migration and metastasis. Accordingly, inhibition of components of this transcription-signaling axis, including TCF12, WNTSA, or YAP, blocked melanoma migration in vitro and metastasis in vivo. These results indicate that epigenetic control of melanoma metastasis involved altered expression of PGC1 alpha and an association with the inherent metabolic state of the tumor.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据